RecruitingNCT04650607
Phage Safety Cohort Study
Sponsor
Hospices Civils de Lyon
Enrollment
100 participants
Start Date
May 9, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This cohort study aims to describe the adverse events related to the use of bacteriophages to treat serious infections, data from the literature being almost non-existent on this subject.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patient 18 years of age or older with a serious infection treated at CRIOAc Lyon by phage therapy
- Patient who did not object to participating in the study
- Patients ayant un poids minimum de 46kg
Exclusion Criteria3
- Patients under guardianship/curatorship
- Patients deprived of liberty
- Pregnant or breastfeeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERAdverse event after injection of phages
rate and description of adverse event after injection of phages
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04650607
Related Trials
Prosthetic Joint Infection : Lessons From Deceased Patients in Critical Care.
NCT071076851 location
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
NCT076095762 locations
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
NCT072143119 locations
Methylene Blue in Total Knee Arthroplasty (TKA)
NCT073249541 location
Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection
NCT062933521 location